<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; LGND</title>
	<atom:link href="http://www.stockbloghub.com/tag/lgnd/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(GSK) GlaxoSmithKline Drug Gets European Commission Approval</title>
		<link>http://www.stockbloghub.com/2010/03/16/gsk-glaxosmithkline-drug-gets-european-commission-approval/30683</link>
		<comments>http://www.stockbloghub.com/2010/03/16/gsk-glaxosmithkline-drug-gets-european-commission-approval/30683#comments</comments>
		<pubDate>Tue, 16 Mar 2010 22:11:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LGND]]></category>
		<category><![CDATA[Ligand Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30683</guid>
		<description><![CDATA[GlaxoSmithKline Plc. (GSK) recently received good news in the form of European approval for its oral thrombopoetin agonist, Revolade (eltrombopag). The European Commission (EC) granted marketing approval to the product for the oral treatment of thrombocytopenia or reduced platelet count in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). Revolade was granted marketing authorization in the European Union for the treatment of ITP in adult patients who have had their spleen removed, and who do not respond to other treatments, like corticosteroids and immunoglobulins therapies. Revolade also gained approval for use as a second-line treatment option for adult patients who cannot get their spleen removed due to contraindications. Revolade’s approval in the EU does not come as a surprise as the product had already received a positive ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/16/gsk-glaxosmithkline-drug-gets-european-commission-approval/30683/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline Gains Positive European Medicines Agency Opinion</title>
		<link>http://www.stockbloghub.com/2010/01/06/gsk-glaxosmithkline-gains-positive-european-medicines-agency-opinion/24270</link>
		<comments>http://www.stockbloghub.com/2010/01/06/gsk-glaxosmithkline-gains-positive-european-medicines-agency-opinion/24270#comments</comments>
		<pubDate>Wed, 06 Jan 2010 17:18:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LGND]]></category>
		<category><![CDATA[Ligand Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24270</guid>
		<description><![CDATA[GlaxoSmithKline (GSK) recently received good news with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion for its oral thrombopoetin agonist, Revolade (eltrombopag). Glaxo is seeking approval for the use of Revolade as an oral treatment for thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). The Committee recommended that Revolade should receive marketing authorization in the European Union for the treatment of ITP in adult patients who have had their spleen removed, and who do not respond to other treatments, like corticosteroids and immunoglobulins therapies. The Committee also recommended the use of Revolade as a second-line treatment option for adult patients who cannot get their spleen removed due to contraindications. Revolade is already approved in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/06/gsk-glaxosmithkline-gains-positive-european-medicines-agency-opinion/24270/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LGND) Ligand Pharmaceuticals to Buy Neurogen</title>
		<link>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310</link>
		<comments>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310#comments</comments>
		<pubDate>Tue, 25 Aug 2009 21:36:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LGND]]></category>
		<category><![CDATA[Ligand Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Neurogen Corporation]]></category>
		<category><![CDATA[NRGN]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13310</guid>
		<description><![CDATA[Yesterday, Ligand Pharmaceuticals Inc. (LGND) announced it has agreed to purchase Neurogen (NRGN) for $11 million in stock as well as certain future cash payments based on licensing deals, real estate sales and other milestones. The deal, which is expected to close by the fourth quarter of this year, has been approved by both company boards. Additionally, Neurogen shareholders, representing approximately 33% of outstanding shares, have already given their nod in favor of the deal. The terms of the deal require Ligand to issue about 4 million new shares to Neurogen shareholders, which is equivalent to a purchase price of 16 cents per common share of Neurogen. Neurogen stockholders would hold 3% of the combined company. The transaction will give Ligand shareholders access to Neurogen&#8217;s partnership with Merck &#38; Co., ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

